Renal Cell Carcinoma CRISPR Knockout Models for Drug Discovery

Renal cell carcinoma (RCC) accounts for approximately 2-3% of all adult malignancies worldwide. According to the World Health Organization (WHO) GLOBOCAN 2022, there were an estimated 431,288 new cases and 179,368 deaths globally in 2022. The incidence is highest in developed countries, with a male-to-female ratio of about 1.5:1. Major risk factors include smoking, obesity, hypertension, and inherited conditions such as von Hippel-Lindau (VHL) disease. The National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) program reports a 5-year relative survival rate of 76% for all stages combined. However, survival drops dramatically with stage: localized disease has a 93% 5-year survival, regional disease 72%, and distant metastatic disease only 15%. This stark disparity underscores the urgent need for improved therapeutic strategies and predictive biomarkers.

RCC is an ideal disease for mechanistic studies due to its well-defined histological subtypes, frequent and recurrent genetic alterations, and the availability of large public datasets such as The Cancer Genome Atlas (TCGA) and the Catalogue of Somatic Mutations in Cancer (COSMIC). The clear cell RCC (ccRCC) subtype, which accounts for 75% of cases, is characterized by near-universal loss of the VHL tumor suppressor gene, leading to constitutive activation of hypoxia-inducible factors (HIFs). This provides a clear genetic entry point for functional studies. Other subtypes, such as papillary RCC (pRCC) and chromophobe RCC (chRCC), have distinct molecular profiles. Key open questions include the mechanisms of resistance to targeted therapies (e.g., tyrosine kinase inhibitors, immune checkpoint inhibitors), the role of metabolic reprogramming, and the identification of synthetic lethal interactions for precision medicine.

The pathogenesis of RCC involves several interconnected pathways. The most prominent is the VHL-HIF axis:

• • VHL loss (mutation, deletion, or hypermethylation) leads to stabilization of HIF-1alpha and HIF-2alpha.
• • Stabilized HIFs translocate to the nucleus and activate transcription of target genes, including VEGF, PDGF, GLUT1, and CA9.
• • This results in angiogenesis, metabolic reprogramming (Warburg effect), and cell proliferation.

Other key pathways include:

1. PI3K/AKT/mTOR pathway: Activated by PIK3CA mutations or PTEN loss, promoting cell growth and survival.

2. SWI/SNF chromatin remodeling complex: Mutations in PBRM1, ARID1A, and SMARCA4 occur in >40% of ccRCC, leading to altered gene expression.

3. Hippo/YAP signaling: Deregulation contributes to proliferation and metastasis.

The following table summarizes the most frequent genetic alterations in ccRCC based on TCGA (Nature 2013) and COSMIC data:

Beyond the VHL-HIF axis, several signaling networks are deregulated in RCC:

• • Hypoxia signaling: HIF-1alpha and HIF-2alpha have overlapping but distinct targets. HIF-2alpha is particularly important in ccRCC and is a therapeutic target.
• • PI3K/AKT/mTOR: Frequently activated due to PTEN loss or PIK3CA mutation. mTOR inhibitors (e.g., everolimus) are used clinically.
• • Wnt/beta-catenin: Activation via beta-catenin stabilization or APC loss contributes to proliferation.
• • MAPK/ERK: Mutations in KRAS or BRAF are rare in ccRCC but may be activated in papillary RCC.
• • Immune checkpoint signaling: PD-L1 expression is upregulated in RCC, making it responsive to immune checkpoint inhibitors.
• • Key nodes for targeted therapy include:
• • VEGFR (angiogenesis)
• • mTOR (cell growth)
• • HIF-2alpha (transcription factor)
• • PD-1/PD-L1 (immune evasion)

Commonly used RCC cell lines and their key mutations are listed below. Organoids derived from patient tumors offer advantages such as preserving tumor heterogeneity and allowing co-culture with immune cells.

Organoid models: Patient-derived organoids (PDOs) retain the genetic and phenotypic features of the original tumor, including VHL mutations and HIF pathway activation. They are suitable for drug sensitivity testing and co-culture with immune cells.

Animal models are essential for in vivo validation of drug targets and mechanisms.

• • Patient-derived xenografts (PDX): Tumor fragments from patients are implanted into immunodeficient mice. They retain the genetic landscape of the original tumor and are used for preclinical drug testing.
• • Genetically engineered mouse models (GEMM): Conditional knockout of Vhl and Pbrm1 in renal tubules leads to ccRCC-like tumors. These models allow study of tumor initiation and progression.
• • Induced models: Chemical carcinogenesis (e.g., using streptozotocin) or orthotopic injection of RCC cell lines into the kidney capsule.
• • Examples:
• • Vhl/Pbrm1 double knockout mouse (ccRCC)
• • Vhl/Trp53 double knockout mouse (ccRCC)
• • Orthotopic injection of 786-O-luciferase cells for metastasis studies

CRISPR/Cas9 technology enables the creation of isogenic cell lines with precise genetic modifications, allowing researchers to study the functional impact of specific mutations in a controlled background. These models are commercially available and sequence-verified, accelerating research by eliminating the need for labor-intensive cloning and validation.

• • Examples of gene-edited RCC cell models:
• • TP53 knockout in 786-O cells: Used to study the role of p53 in RCC progression and drug response.
• • KRAS G12D knock-in in Caki-1 cells: Models the rare but aggressive KRAS-mutant RCC.
• • VHL knockout in ACHN cells: Converts a VHL-wild-type line into a VHL-null background to study HIF pathway activation.
• • PBRM1 knockout in 786-O cells: Investigates the role of PBRM1 loss in chromatin remodeling and gene expression.
• • HIF2A knockout in A498 cells: Validates HIF2A as a therapeutic target.

These models are used for functional genomics, drug screening, and biomarker discovery. They are typically provided with full characterization, including Sanger sequencing, Western blot, and proliferation data.

Gene-edited cell lines are powerful tools for functional genomics. By creating isogenic pairs (e.g., VHL wild-type vs. VHL knockout), researchers can directly attribute phenotypic changes to a specific genetic alteration.

• • Examples:
• • VHL knockout in ACHN cells leads to HIF stabilization, increased VEGF secretion, and enhanced angiogenesis in vitro.
• • PBRM1 knockout in 786-O cells results in altered expression of genes involved in cell cycle and DNA repair, as shown by RNA-seq.
• • TP53 knockout in 786-O cells increases resistance to DNA-damaging agents like cisplatin.

These models allow for the validation of candidate driver genes identified from TCGA and COSMIC.

Isogenic cell line pairs are ideal for drug screening because they eliminate genetic background noise. They can be used to identify drugs that are selectively lethal to cells with a specific mutation.

• • Examples:
• • VHL-null vs. VHL-wild-type isogenic pairs can be screened for compounds that target HIF-2alpha (e.g., belzutifan).
• • PBRM1 knockout cells can be used to test sensitivity to EZH2 inhibitors, as PBRM1 loss creates a dependency on the polycomb repressive complex.
• • Resistance modeling: Chronic exposure of VHL-null cells to a VEGFR inhibitor can select for resistant clones, which can then be analyzed for secondary mutations or pathway rewiring.

CRISPR-based screens in RCC cell lines can identify synthetic lethal interactions and novel biomarkers.

• • Synthetic lethality: In VHL-null cells, a genome-wide CRISPR screen can identify genes that become essential for survival, such as HIF2A or ARNT. These are potential drug targets.
• • Biomarker discovery: Knockout of candidate genes (e.g., CA9, GLUT1) can be used to validate their role as biomarkers for diagnosis or prognosis.
• • Immune evasion: Knockout of PD-L1 in RCC cells can be used to study its role in T-cell activation and immune checkpoint blockade response.

The following public databases provide essential genomic, transcriptomic, and functional data for RCC research: